Immunovant (IMVT) Change in Accured Expenses (2019 - 2025)

Immunovant has reported Change in Accured Expenses for 7 years, with the latest figure at -$7.0 million in Q1 2025.

• For the quarter ending Q1 2025, Change in Accured Expenses fell 145.42% year-over-year to -$7.0 million; the trailing twelve-month figure through Mar 2025 stood at $255000.0 (down 81.1% YoY), and the FY2026 full-year result was -$98000.0, down 138.43% from the prior year.
• Change in Accured Expenses for Q1 2025 stood at -$7.0 million, down from $4.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.5 million in Q1 2024, with the low at -$17.3 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged $508352.9 across 5 years, with a median of $1.2 million in 2021.
• Annual changes were most pronounced in 2021 — Change in Accured Expenses plunged 4725.0% — and 2024, when it surged 1477.81%.
• Immunovant's Change in Accured Expenses stood at $8.3 million in 2021, then plunged by 68.21% to $2.6 million in 2022, then plunged by 302.77% to -$5.3 million in 2023, then jumped by 177.6% to $4.1 million in 2024, then plunged by 269.34% to -$7.0 million in 2025.
• The last three Change in Accured Expenses figures came in at -$7.0 million (Q1 2025), $4.1 million (Q4 2024), and $10.7 million (Q3 2024), per Business Quant data.